Clinical Trial Update: Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating QL1706 in combination with nab-paclitaxel and cisplatin as first-line therapy for advanced or metastatic esophageal squamous c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Nab-paclitaxel (paclitaxel protein-bound)
• QL1706

Snippet

Sponsor: The First Affiliated Hospital of Henan University of Science and Technology | Conditions: QL1706, ESCC | Phase 2 | Status: NOT_YET_RECRUITING